TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
An Oct. 4 MedPage Today opinion by Hana Kahleova argues that routine antibiotic use in food animals is an upstream contributor to drug resistance seen in clinics. It points to China’s 2017 ban on colistin as a feed additive and subsequent declines in resistance, while the scale of the farm-to-patient pathway and the impact of proposed consumer and institutional changes remain uncertain.
A MedPage Today opinion published Oct. 4 argues that antibiotic use in food-animal production is an important upstream source of drug resistance encountered in clinics, and that medical stewardship should extend beyond prescribing. Physician and researcher Hana Kahleova cites the decline in colistin resistance after China restricted the drug’s use as a feed additive, while urging clinicians to support limits on routine preventive antibiotic use in healthy animals.
Kahleova writes that about 70% of antibiotics considered important to human medicine in the United States are sold for use in food animals. She says most of that use is not to treat sick livestock, but the article does not provide the underlying data or define which drugs are included in the estimate. The figure is presented as part of an argument about routine use in intensive animal production, not as a measure of how much resistance in human infections comes from farms.
The article describes several possible routes by which resistant bacteria and resistance genes can spread beyond farms, including meat, water, dust, farm workers and manure. Kahleova points to the emergence of the transferable resistance gene mcr-1, associated with colistin use in Chinese pig farming, as evidence that resistance can cross from food-animal settings into human infections. She says the gene appeared in patient isolates in multiple continents within a few years.
China banned colistin as a feed additive in 2017. Kahleova says resistance to the drug subsequently fell in both animals and people, describing the change as evidence that policy can help preserve antibiotic effectiveness. The opinion does not supply specific study findings or measurements for those declines. It also cites projections that livestock antibiotic use could rise by nearly a third by 2040 and that resistant infections could cause roughly 39 million deaths globally between now and 2050; both are forecasts, not observed future outcomes.
How Farm Use Reaches Clinical Care
Antibiotic resistance can make infections harder to treat by reducing the number of drugs likely to work. The article’s central point is that careful prescribing in hospitals cannot address every source of resistance if antibiotic use elsewhere continues to create pressure for resistant organisms. That does not mean farm use explains any particular patient’s infection: the opinion describes a route of transmission and a public-health concern, not a method for tracing an individual case.
The distinction matters for policy and clinical practice. If routine use in healthy livestock contributes to resistance, reducing that use could complement infection-control measures and responsible prescribing. Kahleova also identifies food purchasing and dietary counseling as possible levers for clinicians and health institutions, including choices about hospital food-service contracts. These are recommendations in an opinion article; it does not quantify how much they would reduce resistance or demonstrate that they can replace regulation.
As an affiliate, we earn on qualifying purchases.
Colistin and the 2017 Chinese Ban
Colistin is an antibiotic used as a reserve option for some difficult-to-treat infections. The article says it was also used as a low-cost growth promoter on Chinese pig farms before the country prohibited that feed-additive use. The emergence and international spread of mcr-1 drew attention to how resistance genes can move between bacteria and cross national borders.
Kahleova frames the policy change as a real-world example of a targeted restriction being followed by lower resistance in animals and people. The World Health Organization, she notes, has called for stopping routine preventive antibiotic use in animals that are not sick. That position is not a call to withhold treatment from ill livestock: the article explicitly distinguishes routine prevention in healthy animals from veterinary care for animals that need antibiotics.
As an affiliate, we earn on qualifying purchases.
What the Evidence Does Not Quantify
The opinion argues that farm antibiotic use contributes to resistance in people, but it does not estimate what proportion of resistant human infections originates in food-animal production. It also does not provide the detailed sources behind its 70% U.S. sales figure, the projected rise in livestock use, or its description of resistance declines after China’s ban. The article’s claims should not be read as proof that a given resistant infection came from a farm.
The likely effects of consumer choices, hospital purchasing, and clinician counseling are also unquantified in the piece. How much these actions would change antibiotic use in agriculture, and what policies would be needed alongside them, remain open questions. The article does not argue that veterinary antibiotics should be eliminated; it calls for reducing routine use in animals that are not sick.
As an affiliate, we earn on qualifying purchases.
Policy and Purchasing Decisions Ahead
Kahleova urges clinicians to advocate for limits on routine preventive antibiotic use through professional societies and to raise the issue in institutional food purchasing. She also recommends connecting plant-forward dietary counseling with the wider effects of food production. These are proposed actions, not announced policy changes. The opinion does not identify a new regulation, implementation timetable, or specific next decision by government or health systems.
Further assessment of the evidence would require clear reporting on antibiotic sales and use by animal species and purpose, as well as surveillance that can track resistance across animals, food, the environment, and human infections. Until then, the article’s message is that clinical prescribing is one part of stewardship, while the size and precise routes of the farm-to-clinic contribution remain difficult to establish from the material it presents.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the main claim of the MedPage Today article?
Physician Hana Kahleova argues that routine antibiotic use in food-animal production contributes to drug resistance that can reach human patients, and that stewardship should address this source as well as prescribing in clinics.
Does the article say antibiotics should never be used in livestock?
No. It distinguishes routine preventive use in healthy animals from treatment for sick animals, which Kahleova says remains necessary.
What happened after China restricted colistin use as a feed additive?
Kahleova says colistin resistance fell in animals and people after China’s 2017 ban. The opinion does not provide specific measurements for those declines.
Does the article establish that a particular patient’s infection came from a farm?
No. It discusses pathways by which resistant organisms or genes may spread and cites mcr-1, but it does not trace the source of any individual infection.
What actions does Kahleova propose?
She calls for clinicians to support limits on routine preventive antibiotic use in healthy animals and suggests that dietary counseling and institutional food purchasing could also influence demand. The article does not quantify the effect of those steps.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
